Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Safety. Found 8 abstracts

Davis BJ, Horwitz EM, Lee WR, Crook JM, Stock RG, Merrick GS, Butler WM, Grimm PD, Stone NN, Potters L, Zietman AL, Zelefsky MJ. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy. 2012 Jan;11(1):6-19.   PMCID: not NIH funded
Fizazi K, De Bono JS, Flechon A, Heidenreich A, Voog E, Davis NB, Qi M, Bandekar R, Vermeulen JT, Cornfeld M, Hudes GR. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. European Journal of Cancer. 2012 Jan;48(1):85-93.   PMCID: Private funding
Rosenthal SA, Bittner NH, Beyer DC, Demanes DJ, Goldsmith BJ, Horwitz EM, Ibbott GS, Lee WR, Nag S, Suh WW, Potters L. AMERICAN SOCIETY FOR RADIATION ONCOLOGY (ASTRO) AND AMERICAN COLLEGE OF RADIOLOGY (ACR) PRACTICE GUIDELINE FOR THE TRANSPERINEAL PERMANENT BRACHYTHERAPY OF PROSTATE CANCER. International Journal of Radiation Oncology Biology Physics. 2011 Feb;79(2):335-41.   PMCID: PMCID: PMC3030655 [Available on 2012/2/1]
Talamonti MS, Small W, Mulcahy MF, Wayne JD, Attaluri V, Colletti LM, Zalupski MM, Hoffman JP, Freedman GM, Kinsella TJ, Philip PA, McGinn CJ. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Annals of Surgical Oncology 13 (2): 150-158 Feb 2006. 2006 Feb;13(2):150-8.
Borghaei H, Schilder RJ. Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Seminars in Nuclear Medicine. 2004 Jan;34(1 Suppl 1):4-9.
Young RC, Wilson CM. Cancer prevention: past, present, and future. Clin Cancer Res. 2002 Jan;8(1):11-6.
Langer CJ, Hoffman JP, Ottery FD. Clinical significance of weight loss in cancer patients: rationale for the use of anabolic agents in the treatment of cancer-related cachexia. Nutrition. 2001 Jan;17(1 Suppl):S1-20.
Horwitz EM, Hanks GE. Three-dimensional conformal radiation therapy: what are the costs and benefits?. Surg Oncol Clin N Am. 2000 Jul;9(3):455-67, viii.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Safety

Safety Human Brachytherapy Neoplasms metabolism Radiotherapy Radiotherapy Dosage therapy Dosimetry Treatment Outcome methods seed implantation drug therapy Appetite Stimulants pathology trial interstitial-brachytherapy Survival Rate Deoxycytidine therapeutic use interstitial brachytherapy mortality quality-of-life administration & dosage Weight Loss ae [Adverse Effects] Health Resources tu [Therapeutic Use] Outcome Assessment (Health Care) randomized multicenter trial mice Prostatic neoplasms Health Care Costs ixabepilone Pancreatic Neoplasms prevention & control Non-Hodgkin Lymphoma body-mass index survival outcomes Yttrium Radioisotopes rt [Radiotherapy] cells Follow-Up Studies Siltuximab 1980 aryulu kkn-international journal of radiation oncology biology physics-v6-p1261 etiology Maximum Tolerated Dose Treatment efficacy androgen deprivation therapy Radioimmunotherapy Prednisone Interstitial Survival Analysis Mitoxantrone Nutrition Disorders volume histogram analysis interobserver variability end-points complications Standard external-beam radiation biochemical failure Middle Aged survival interleukin-6 physiopathology Male Animal Radiation therapy HIV Wasting Syndrome Monoclonal Antibodies Comparative Study radical prostatectomy Neoadjuvant Therapy adverse effects Oxandrolone analogs & Cachexia retention Nutritional Status Nutritional Support Quality Assurance Body Weight Antineoplastic Antimetabolites Female Chemoprevention Quality assurance postimplant acute urinary derivatives Cost-Benefit Analysis external-beam radiotherapy androgen suppression Prostate cancer phase-iii trial Interleukin-6 docetaxel Non-US Gov't Support Nutrition Assessment economics dosimetric analysis Conformal Radiotherapy Anabolic Steroids surgery Prostate Cancer Forecasting 80 and over Aged Biological Tumor Markers Guideline 2010 bono js-35 ann c eur soc med pubic arch interference Aged prednisone CNTO 328 monoclonal antibody
Last updated on Monday, July 13, 2020